logo-loader

Avacta Group's Bach BioSciences deal 'an exciting step'

Published: 22:21 31 Jul 2018 AEST

Capital Network analyst Riccardo Lowi discusses Avacta Group Plc's (LON:AVCT) development partnership with Bach BioSciences as well as the news it's making shares available via subscription and a placing to bring in £11.4mln.

Lowi says the R&D collaboration with Bach is a very exiting step, potentially leading to a pre-clinical deal with big pharma in the next 12-18 month.

On Avacta's fundraise, he says the move should support operations well into calendar year 2020.

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

13 hours, 45 minutes ago